Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum

X
Trial Profile

Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nintedanib (Primary) ; Carboplatin; Paclitaxel
  • Indications Adenocarcinoma; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Acronyms ARCAGY-GINECO; CHIVA; GINECO GINEGEPS
  • Most Recent Events

    • 24 Oct 2023 Results assessing links between KELIMTM values and pathological response, and changes in TILs, in ovarian cancer patients treated with neo-adjuvant chemotherapy (NACT) +/- interval debulking surgery, presented at the 48th European Society for Medical Oncology Congress.
    • 06 Jun 2023 Results (n=105) assessing the CD47 expression in ovarian cancer patients at diagnosis and after neoadjuvant chemotherapy and its relationship to other iTME features, including circulating level of thrombospondin-1 (TSP-1), presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 25 Jan 2023 Results assessing the impact of combining nintedanib with neoadjuvant chemotherapy (NACT) for epithelial ovarian cancer published in the Gynecologic Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top